ABCL - CIK 0001703057
The table below shows AbCellera Biologics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$131.29M | -$108.56M | -$43.88M | $277.36M | $244.58M | $22.69M |
| Capital expenditure | $42.77M | $78.40M | $76.95M | $70.66M | $58.45M | $9.67M |
| Investing cash flow | $87.75M | $121.41M | -$221.11M | -$352.63M | -$332.25M | -$119.78M |
| Dividends paid | - | - | - | - | - |
AbCellera Biologics Inc. reported operating cash flow of -$131.29M for fiscal year 2025. That is down 20.9% from -$108.56M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $2.69M (FY 2019) to -$131.29M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $14.08M | $12.77M | $10.36M | -$1.63M | -$3.89M | $683.65M |